Skip to main content

Market Overview

Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research

Share:
Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research

The global laryngeal cancer therapeutics market is expected to grow by $635.07 million during 2021-2025 helped by Amgen Inc (NASDAQ: AMGN) and AstraZeneca Plc (NYSE: AZN) as key contributors to growth, according to a study by research firm Technavio. 

What Happened: The laryngeal cancer therapeutics market will grow at a CAGR of 6.50% during 2021-2025 period. This marks a significant slow down compared to the 2020 growth estimates due to the impact of the COVID-19 pandemic, according to the report. 

The high mortality rate and the increasing prevalence of laryngeal cancer have resulted in a growing need for novel therapeutics.

Several pharmaceutical companies have undertaken research and development on novel PD-1 inhibitors, PD-L1 inhibitors which are associated with head and neck cancers.

According to the report, North America will contribute about 43% of the growth during the forecast period led by the United States as a key contributor. However, growth in the region will be slower than that of Asia, the report said.

Why Is It Important: The increasing preference for therapeutics to treat various head and neck cancer indications is one of the prime factors that will facilitate the laryngeal cancer therapeutics market growth in North America over the forecast period. 

Key players include Amgen, which provides Vectibix (panitumumab) as a first-line treatment to patients and AstraZeneca, which combats metastatic and resistant disease by defining new biomarkers and therapeutic targets. Other players include Bristol-Myers Squibb Co (NYSE: BMY), Roche Holdings AG Basel (OTC: RHHBY) and Merck & Co. Inc (NYSE: MRK).

 

Price Action: AstraZeneca shares closed slightly higher at $50.07 on Wednesday and Amgen shares were up 1.6% at $244.27.

Latest Ratings for AZN

DateFirmActionFromTo
Apr 2021Argus ResearchDowngradesBuyHold
Mar 2021JefferiesUpgradesHoldBuy
Mar 2021SVB LeerinkMaintainsOutperform

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

 

Related Articles (AMGN + AZN)

View Comments and Join the Discussion!

Posted-In: Laryngeal Cancer laryngeal cancer therapeuticsAnalyst Color Biotech Long Ideas Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
HR.UNCIBCMaintains17.0
FDGECIBCMaintains20.0
SNCCIBCMaintains40.0
APENLake StreetInitiates Coverage On12.0
PATHMacquarieInitiates Coverage On69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com